Principal Financial Group
PLRX icon

Principal Financial Group’s Pliant Therapeutics PLRX Stock Holding History

Principal Financial Group’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8,635
Closed -$340K – 2635
2021
Q1 		$340K Buy
+8,635
New +$280K ﹤0.01% 2241

Other funds holding PLRX

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Principal Financial Group's PLRX Position: Q2 2021 in Review

Principal Financial Group sold out of Pliant Therapeutics (PLRX) in Q2 2021, closing a stake of 8,635 shares — an estimated $340K sold.

Principal Financial Group first reported a position in PLRX in Q1 2021 and held it in 1 quarter. The position peaked at $340K in Q1 2021. 81 funds tracked by Wall St. Rank hold PLRX as of Q2 2021.

  • Principal Financial Group reported no remaining Pliant Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Principal Financial Group sold 8,635 Pliant Therapeutics shares in Q2 2021, an estimated $340K.
  • Principal Financial Group first reported a position in Pliant Therapeutics in Q1 2021 and held it in 1 quarter.
  • Principal Financial Group's Pliant Therapeutics position peaked at $340K in Q1 2021.
  • 81 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2021.

Based on Principal Financial Group's 13F filing for Q2 2021, filed 10 Aug 2021.